Compare HubSpot Inc (HUBS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Regeneron Pharmaceuticals Inc — how do they compare? HubSpot Inc trades at $231.12 (market cap $11.56B), while Regeneron Pharmaceuticals Inc trades at $740.01 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 6.6× HubSpot Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| HUBS | REGN | |
|---|---|---|
Market Cap | $11.56B | $76.14B |
Volume | 1,891,287 | 500,239 |
Sector | Technology | Health |
52-Week High | $494.58 | $852.03 |
52-Week Low | $170.39 | $557.73 |
Typical Hold Time | 78 Days | 107 Days |
Enterprise Value | $10.46B | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $220.31, up 1.55% on the day, with a bearish technical signal but strong fundamental momentum. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth is robust, rising from $1.7B in 2022 to $3.1B in 2025, while net income turned positive in 2024. Recent news highlights an AI-focused strategy unveiled at Analyst Day and a deepened partnership with OpenAI, targeting margin expansion and SMB growth.
The outlook is cautiously optimistic, with a consensus price target of $243.65 implying ~11% upside. Key opportunities include sustained revenue growth, margin improvement, and AI integration, but risks involve high valuation multiples (P/E 78.39), competitive pressures, and insider selling. Wall Street sentiment is bullish (57% buy ratings), though technical indicators suggest near-term resistance.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
